loading...
Distributed by Mapi Research Trust
Distributed by Mapi Research Trust
Developed in 2013
Otsuka Pharmaceutical Development & Commercialization, Inc (USA)
Polycystic Kidney, Autosomal Dominant For more information on this rare disease, please consult the following link: Orphanet page
Cole J, Cheng R, Oberdhan D, Krasa H, Hays RD. Psychometric analyses of patient-reported outcome instruments for Autosomal Dominant Polycystic Kidney Disease. Value in Health. 2015 May;16(3):A183 (Poster Abstract)
Oberdhan D, Krasa H, Schaefer C, Cole J. Health-Related Quality Of Life (HRQoL) Measures In Autosomal Dominant Polycystic Kidney Disease (ADPKD). Value in Health. 2015;18(7). (Abstract)
Oberdhan D, Cole JC, Krasa HB, Cheng R, Czerwiec FS, Hays RD, Chapman AB, Perrone RD. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. Am J Kidney Dis. 2017 Nov 14. pii: S0272-6386(17)30951-4. (Full Text Article)
Otsuka Pharmaceutical Development & Commercialization, Inc (USA)
Otsuka Pharmaceutical Development & Commercialization, Inc.
2440 Research Boulevard
Rockville, MD 20850
USA
Phone: +1-240-683-3517 |
Fax: +1-301-721-7517 |
Contact person:
Dorothee Oberdhan, MS
Senior Manager, HEOR and Outcomes Management
E-mail: dorothee.oberdhan@otsuka-us.com
Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66
You may access available translations of the questionnaire directly (see tutorial). Should you not see the Download button, please contact us.
All requests have to be submitted through our online request management:
Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.
The listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.
The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.
For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).
If you wish to translate the questionnaire:
Access to advanced descriptions of Clinical Outcome Assessments (COAs)